- Vaccine's human trial was successful, claims Sechinov University of Russia, trial began on 18 June
- Russia-based pharmaceutical company R-Farm also recently prepared Kovid-19 drug Coronavir, approved for use on humans.
Jul 13, 2020, 12:03 PM IST
Russia's Sechinov University claims to have developed the world's first corona vaccine. According to the university, the vaccine trial on humans has been successful. Alexander Lukashev, director of Sechnov University's Institute of Medical Parasitology Tropical and Vector-Born Diseases, says, "Our aim was to successfully produce the vaccine of Kovid-19 to protect humans."
According to Alexander, the vaccine has been tested for safety. Soon it will be available in the market.
According to Vadim Tarasov, director of the Institute for Translational Medicine and Biotechnology, the Gamely Institute of Epidemiology and Microbiology has designed the vaccine. The trial started on 18 June by Sechinov University. Which has been successful.
Russia made Kovid-19 drug 'Coronavir'
Recently, Russia-based pharmaceutical company R-Farm also developed a new drug for the treatment of Kovid-19. The new antiviral drug is named coronavir. After the clinical trial, the drug was allowed to treat Kovid-19 patients. The company claims that this drug works better on Corona patients. Coronavir inhibits virus replication (increasing virus count).
Company claims, it strikes the root of Kovid-19
The company claims that 'coronavir' is the first such drug in the country which is solely for the treatment of Kovid-19 patients. Corona cases are increasing worldwide but the root cause of the problem is the virus. In infected patients, this drug prevents the increase in the number of corona.
55 percent improvement seen
According to the Russian pharma company R-Farm, Kovid-19 patients taking coronavir and other therapeutic drugs during clinical trials were compared. The report revealed that 55 percent more improvement was observed in patients taking the new medicine compared to other medicines and therapies.
The company claims that this claim targets the disease rather than focusing on the symptoms of Kovid-19. The difference was understood after 14 days of giving this medicine to patients. A clinical trial revealed that 77.5 percent of patients did not receive a coronavirus on the fifth day of giving coronavir.